GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ceapro Inc (TSXV:CZO) » Definitions » Cyclically Adjusted Price-to-FCF

Ceapro (TSXV:CZO) Cyclically Adjusted Price-to-FCF : (As of May. 24, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Ceapro Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ceapro Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Ceapro's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ceapro Cyclically Adjusted Price-to-FCF Chart

Ceapro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1,074.05 -

Ceapro Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,074.05 - - - -

Competitive Comparison of Ceapro's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Ceapro's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ceapro's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ceapro's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ceapro's Cyclically Adjusted Price-to-FCF falls into.



Ceapro Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Ceapro's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Ceapro's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.03/125.0724*125.0724
=-0.030

Current CPI (Dec. 2023) = 125.0724.

Ceapro Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.020 98.604 -0.025
201406 -0.016 99.473 -0.020
201409 -0.001 99.394 -0.001
201412 -0.003 98.367 -0.004
201503 -0.010 99.789 -0.013
201506 -0.004 100.500 -0.005
201509 -0.002 100.421 -0.002
201512 0.012 99.947 0.015
201603 0.011 101.054 0.014
201606 -0.014 102.002 -0.017
201609 0.001 101.765 0.001
201612 0.001 101.449 0.001
201703 -0.018 102.634 -0.022
201706 -0.013 103.029 -0.016
201709 0.008 103.345 0.010
201712 -0.007 103.345 -0.008
201803 0.001 105.004 0.001
201806 -0.005 105.557 -0.006
201809 -0.013 105.636 -0.015
201812 -0.026 105.399 -0.031
201903 0.004 106.979 0.005
201906 0.006 107.690 0.007
201909 0.005 107.611 0.006
201912 -0.006 107.769 -0.007
202003 0.007 107.927 0.008
202006 0.027 108.401 0.031
202009 0.024 108.164 0.028
202012 -0.009 108.559 -0.010
202103 0.000 110.298 0.000
202106 0.027 111.720 0.030
202109 0.003 112.905 0.003
202112 0.006 113.774 0.007
202203 0.014 117.646 0.015
202206 0.033 120.806 0.034
202209 0.020 120.648 0.021
202212 0.012 120.964 0.012
202303 -0.015 122.702 -0.015
202306 -0.015 124.203 -0.015
202309 0.001 125.230 0.001
202312 -0.030 125.072 -0.030

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ceapro  (TSXV:CZO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Ceapro Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Ceapro's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Ceapro (TSXV:CZO) Business Description

Industry
Traded in Other Exchanges
Address
7824-51 Avenue NW, Edmonton, AB, CAN, T6E 6W2
Ceapro Inc is engaged in the development and marketing of various health and wellness products and technology relating to plant extracts. Its operating segment is the active ingredient product technology industry which involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Active ingredients produced include oat beta glucan and avenanthramides. The group derives revenue from the U.S., Germany, China, Canada and other countries, of which prime revenue is generated from the U.S.

Ceapro (TSXV:CZO) Headlines

No Headlines